Fig 1: Representative Immunohistochemistry (IHC) staining images of ASPHD1 in normal skin and SKCM tissues. (A-D) ASPHD1 was not detected or low expression (< 25%) in normal skin tissues. (E-F) ASPHD1 was moderate expression (> 75%) in SKCM tissues
Fig 2: Functional enrichment analysis of ASPHD1-related DEGs in SKCM. (A) Annotations of GO enrichment analysis include biological process (BP), cellular components (CC), and molecular function (MF) categories. (B) KEGG pathway annotations, copyright permission of KEGG pathway maps was obtained from Kanehisa Laboratories. (C) Top 10 correlation genes of ASPHD1. Red means positive regulation and green means negative regulation. (D) Merged enrichment plots from the gene set enrichment analysis (GSEA).
Fig 3: Kaplan-Meier curves comparing the low and high ASPHD1 expression in SKCM patients. Survival curves of overall survival (OS) in all SKCM patients (A) and metastatic patients (B) from TCGA. (C) Survival curves of OS in SKCM from TISIDB. (D) Forest plot for the multivariate Cox proportional hazard regression model. * p < 0.05, ** p < 0.01, *** p < 0.001
Fig 4: Association of ASPHD1 expression and immunomodulators in SKCM. (A) Correlation between ASPHD1 expression and immunoinhibitors in SKCM from TISIDB. (B) Correlation between ASPHD1 expression and immunostimulators in SKCM from TISIDB.
Fig 5: (A) The neighbor gene network was performed by protein-protein interaction network using STRING. (B) The gene co-expression networks of ASPHD1 in SKCM were conducted by the Coexpedia database
Supplier Page from Abcam for Anti-ASPHD1 antibody